No. | Disease | Conditioning Regimen | GVHD Prophylaxis | Cell number | Engraftment (days) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
NC × 108/kg | CD34 × 106/kg | ANC | PLt | |||||||||
PB/BM | PB/BM | > 0.5 × 109/L | > 20 × 109/L | > 50 × 109/L | Acute GVHD | chronic GVHD | Survival (Month) | Cause of death | ||||
1 | VSAA-I | CY/ALG | CsA+MMF | 5.95/3.06 | 3.07/0.89 | 11 | 15 | 18 | N | skin | 80+ | |
2 | VSAA-I | CY/ALG | CsA+MMF | 2.47/1.9 | 2.39/0.7 | 11 | 14 | 18 | N | N | 62+ | |
3 | SAA-II | CY/ALG | CsA+MMF | 2.91/2.6 | 2.33/1.48 | 15 | 47 | 53 | 7 | Late graft | ||
N | N | Rejection | ||||||||||
4 | VSAA-I | CY/ALG | CsA+MMF | 2.46/2.21 | 5.66/0.95 | 14 | 22 | 34 | N | N | 54+ | |
5 | SAA-I | CY/ALG | CsA+MMF | 6.47/1.88 | 5.3/0.47 | 10 | 20 | 50 | N | N | 9 | Infection |
6 | SAA-I | CY/ALG | CsA+MMF | 4.54/3.87 | 2.81/1.1 | 12 | 20 | 32 | N | N | 46+ | |
7 | VSAA-I | CY/ALG | CsA+MMF | 6.17/1.0 | 1.54/0.3 | 14 | 30 | 35 | N | N | 30+ | |
8 | SAA-I | CY/ALG | CsA+MMF | 4.64/1.86 | 4.45/0.71 | 11 | 15 | 18 | N | N | 30+ | |
9 | SAA-II | Flu/CY/ALG | CsA+MMF | 5.05/1.14 | 1.36/0.33 | 12 | 17 | 20 | N | N | 29+ | |
10 | SAA-II | Flu/CY/ALG | CsA+MMF | 3.75/1.47 | 4.2/0.66 | 12 | 15 | 16 | N | N | 28+ | |
11 | SAA-I | CY/ALG | CsA+MMF | 2.98/1.77 | 6.62/0.9 | 10 | 15 | 20 | N | N | 26+ | |
12 | VSAA-I | CY/ALG | CsA+MMF | 7.80/2.6 | 5.7/0.85 | 12 | 14 | 15 | N | N | 26+ | |
13 | SAA-II | Flu/CY/ALG | CsA+MMF | 5.86/2.1 | 5.03/0.92 | 13 | 16 | 16 | N | N | 20+ | |
14 | VSAA-I | CY/ALG | CsA+MMF | 2.15/1.9 | 0.49/1.14 | 23 | 27 | 35 | N | N | 5 | Infection |
15 | SAA-I | CY/ALG | CsA+MMF | 8.3/0.77 | 1.66/0.17 | 16 | 29 | 48 | N | N | 7+ | |
Median (range) | 4.64(2.15-8.3)/1.9(0.77-3.87) × 108/kg | 3.07(0.49-6.62)/0.85(0.17-1.48) × 106/kg | Day 12 (10-23) | Day 16.5 (14-47) | Day 20 (15-53) | Month 27 (7-80) |